Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor by Heinrich Michael C, Maki Robert G, Corless Christopher L, Antonescu Cristina R, Harlow Amy, Griffith Diana, Town Ajia, McKinley Arin, Ou Wen-Bin, Fletcher Jonathan A, Fletcher Christopher D M, Huang Xin, Cohen Darrel P, Baum Charles M, Demetri George D in Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008).

[PMID: 18955458] PubMed


Most gastrointestinal stromal tumors (GISTs) harbor mutant KIT or platelet-derived growth factor receptor alpha (PDGFRA) kinases, which are imatinib targets. Sunitinib, which targets KIT, PDGFRs, and several other kinases, has demonstrated efficacy in patients with GIST after they experience imatinib failure. We evaluated the impact of primary and secondary kinase genotype on sunitinib activity.

[ hide abstract ]

Discussed In Paper


Dosing Information

No dosing information annotated.